- 询价
- 2025年12月10日
14 年金牌会员
企业认证
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 技术资料
- 物种来源：
人
- 是否是肿瘤细胞：
0
- 细胞形态：
淋巴样
- 细胞类型：
T淋巴细胞
- 运输方式：
冻存运输
- 器官来源：
外周血
- 生长状态：
悬浮生长
- 库存：
大量
- 相关疾病：
白血病
- ATCC Number：
CRL-2264™
- 年限：
4 years
| Designations: | CEM/C2 | ||
| Depositors: | WG Harker | ||
| Biosafety Level: | 1 | ||
| Shipped: | frozen | ||
| Medium & Serum: | See Propagation | ||
| Growth Properties: | suspension | ||
| Organism: | Homo sapiens | ||
| Morphology: | lymphoblast |
||
| Source: | Organ: peripheral blood Disease: acute lymphoblastic leukemia Cell Type: T lymphoblast; |
||
| Permits/Forms: | In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location. | ||
| DNA Profile (STR): | Amelogenin: X CSF1PO: 11 D13S317: 11,12 D16S539: 10,13 D5S818: 13 D7S820: 9,8.3 THO1: 6,7 TPOX: 8 vWA: 17,19 |
||
| Age: | 4 years | ||
| Gender: | female | ||
| Ethnicity: | Caucasian | ||
| Comments: | CEM/C2 is a camptothecin (CPT) resistant derivative of the human T cell leukemia cell line CCRF-CEM (see ATCC CCL-119 ). The cell line was selected and subcloned in 1991 for resistance to CPT. The cells are approximately 970-fold less sensitive to CPT than the parental CEM cells. CEM/C2 cells exhibit cross resistance to both the water soluble (topotecan) and water insoluble (9-amino-CPT and 10,11-methylenedioxy-CPT) analogs of CPT. CEM/C2 cells are also cross resistant to etoposide, dactinomycin, bleomycin, mitoxantrone, 4'-(9-acridinylamino)methanesulfon-m-anisidide, and the anthracyclines daunorubicin and doxorubicin but retain sensitivity to the Vinca alkaloid vincristine. CEM/C2 cells display atypical multidrug resistance (MDR), altered topoisomerase I catalytic activity and a unique topoisomerase I mutation (Asn722Ser). Resistance to CPT is stable for up to six months. |
||
| Propagation: | ATCC complete growth medium: The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%. Temperature: 37.0°C |
||
| Subculturing: | Protocol: Cultures can be maintained by addition or replacement of medium. Establish new cultures at 2 X 10 exp5 viable cells/ml and maintain between 1 X 10 exp5 and 2 X 10 exp6. Medium Renewal: Every 2 to 3 days |
||
| Preservation: | Freeze medium: Complete growth medium 95%; DMSO, 5% Storage temperature: liquid nitrogen vapor temperature |
||
| Doubling Time: | 30 hrs | ||
| Related Products: | Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2001 recommended serum:ATCC 30-2020 parental cell line:ATCC CCL-119 |
||
| References: | 22339: Kapoor R, et al. Altered topoisomerase I expression in two subclones of human CEM leukemia selected for resistance to camptothecin. Oncol. Res. 7: 83-95, 1995. PubMed: 7579731 23117: Fujimori A, et al. Mutation at the catalytic site of topoisomerase I in CEM/C2, a human leukemia cell line resistant to camptothecin. Cancer Res. 55: 1339-1346, 1995. PubMed: 7882333 |
||
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
技术资料暂无技术资料 索取技术资料
CEM/C2
询价
